Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis.

OBJECTIVE Pseudomonas aeruginosa is an opportunistic pathogen that infects the lungs of people with cystic fibrosis (CF) and is the most common cause of chronic respiratory infections with high morbidity and mortality in CF patients. This study aimed to evaluate the pattern of antibiotic resistance of P. aeruginosa strains from patients with CF using a systematic review and meta-analysis. METHODS A comprehensive and systematic search was performed for relevant articles until August 2021 in the following database: PubMed, Scopus, Embase, and Web of Science. Finally, 122 articles with appropriate criteria were included in the meta-analysis. To estimate weighted pooled proportions Freeman-Tukey double arcsine transformation was performed using Metaprop command in Stata software version 17.1. RESULTS 122 studies evaluated the pattern of P. aeruginosa antibiotic resistance from different antibiotic classes in patients with CF. Cefotaxime had the highest resistance rate of 67% (95% CI 53_80%), while colistin had the lowest 5% (95% CI 2-8%). CONCLUSION High resistance to most of the studied antibiotics was observed. The high antibiotic resistance observed is worrying and it indicates the need to monitor using of antibiotics. In addition, colistin is the most appropriate treatment choice, but more randomized controlled trial studies are recommended.

• Publication year

  2022

• Venue

  Microbial Pathogenesis

• Publication date

  2022-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.micpath.2022.105461PMID 35240288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

  2021cited by this paper
• Prospectively predicting Pseudomonas aeruginosa infection/s using routine data from the UK cystic fibrosis register

  2021cited by this paper
• In vitro activity of Fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains.

  2020cited by this paper
• Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis

  2020cited by this paper
• Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis

  2020cited by this paper
• Pseudomonas Aeruginosa: Genetic Adaptation, A Strategy for its Persistence in Cystic Fibrosis

  2020cited by this paper
• In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.

  2020cited by this paper
• Pseudomonas aeruginosa Modulates the Antiviral Response of Bronchial Epithelial Cells

  2020cited by this paper
• Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface

  2019cited by this paper
• Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series

  2019cited by this paper
• Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

  2019cited by this paper
• Survey on Some Carbapenems and Colistin Resistance Genes Among Pseudomonas aeruginosa Isolates from Burn and Cystic Fibrosis Patients, Tehran, Iran

  2019cited by this paper
• Performance evaluation of the βLACTA™ Test for rapid detection of ceftazidime resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

  2019cited by this paper
• Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics

  2019cited by this paper
• Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

  2019cited by this paper
• Pseudomonas aeruginosa in cystic fibrosis: A chronic cheater

  2019cited by this paper
• Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis

  2019cited by this paper
• Cystic Fibrosis: Pathophysiology of Lung Disease

  2019cited by this paper
• Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment

  2019cited by this paper
• Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

  2018cited by this paper
• Antibiotic resistance: a rundown of a global crisis

  2018cited by this paper
• The Pseudomonas aeruginosa Pan-Genome Provides New Insights on Its Population Structure, Horizontal Gene Transfer, and Pathogenicity

  2018cited by this paper
• Phenotypic and genetic resistance traits of Pseudomonas aeruginosa strains infecting cystic fibrosis patients: A French cohort study.

  2018cited by this paper
• Heterogeneous Antimicrobial Susceptibility Characteristics in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2018cited by this paper
• Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.

  2018cited by this paper
• Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF)

  2018cited by this paper
• In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.

  2018cited by this paper
• Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates.

  2018cited by this paper
• Chronic infection sustained by a Pseudomonas aeruginosa High-Risk clone producing the VIM-1 metallo-β-lactamase in a cystic fibrosis patient after lung transplantation.

  2018cited by this paper
• Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study.

  2017cited by this paper
• Towards individualized diagnostics of biofilm-associated infections: a case study

  2017cited by this paper
• The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung

  2017cited by this paper
• Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

  2017cited by this paper
• Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern.

  2016cited by this paper
• Cystic Fibrosis Isolates of Pseudomonas aeruginosa Retain Iron-Regulated Antimicrobial Activity against Staphylococcus aureus through the Action of Multiple Alkylquinolones

  2016cited by this paper
• Long-term effects of azithromycin in patients with cystic fibrosis.

  2016cited by this paper
• Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene

  2016cited by this paper
• Cystic fibrosis lung environment and Pseudomonas aeruginosa infection

  2016cited by this paper
• The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions

  2016cited by this paper
• Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study.

  2016cited by this paper
• Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade

  2015cited by this paper
• In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.

  2015cited by this paper
• Spread of Efflux Pump Overexpressing-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa by using an Efflux Pump Inhibitor

  2015cited by this paper
• Low‐level resistance and clonal diversity of Pseudomonas aeruginosa among chronically colonized cystic fibrosis patients

  2015cited by this paper
• Autoinducer-2 regulates Pseudomonas aeruginosa PAO1 biofilm formation and virulence production in a dose-dependent manner

  2015cited by this paper
• Investigating the Link Between Imipenem Resistance and Biofilm Formation by Pseudomonas aeruginosa

  2014cited by this paper
• Pseudomonas aeruginosa Biofilms in Disease

  2014cited by this paper
• Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.

  2014cited by this paper
• Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients from Two Brazilian Cities

  2013cited by this paper
• Frequency of fungi in respiratory samples from Turkish cystic fibrosis patients

  2013cited by this paper
• Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.

  2013cited by this paper
• Phenotypic characterization and PCR-Ribotypic profile of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Iran

  2013cited by this paper
• Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

  2013cited by this paper
• Genetic relatedness of Pseudomonas aeruginosa isolates among a paediatric cystic fibrosis patient cohort in Ireland.

  2012cited by this paper
• Bacteriology of the paranasal sinuses in pediatric cystic fibrosis patients.

  2012cited by this paper
• Drug resistance pattern of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients at Isfahan AL Zahra hospital, Iran (2009–2010)

  2012cited by this paper
• Molecular epidemiology ofPseudomonas aeruginosa in cystic fibrosis patients from Southeast Austria

  2012cited by this paper
• Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study

  2012cited by this paper
• Pseudomonas aeruginosa Syntrophy in Chronically Colonized Airways of Cystic Fibrosis Patients

  2012cited by this paper
• Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).

  2011cited by this paper
• Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients

  2011cited by this paper
• Cystic and Non-Cystic Fibrosis Pseudomonas aeruginosa Isolates are not Differentiated by the Quorum-Sensing Signaling and Biofilm Production

  2011cited by this paper
• Antibiotic and metal resistance among hospital and outdoor strains of Pseudomonas aeruginosa.

  2011cited by this paper
• Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals

  2011cited by this paper
• Characterization of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients by different typing methods.

  2011cited by this paper
• Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.

  2011cited by this paper
• Nutritional requirement among Pseudomonas aeruginosa isolates recovered from respiratory clinical specimens at a tertiary hospital from South of Brazil

  2011cited by this paper
• Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

  2010cited by this paper
• Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008

  2010cited by this paper
• The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection.

  2010cited by this paper
• Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index.

  2010cited by this paper
• Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

  2010cited by this paper
• Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum.

  2010cited by this paper
• Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

  2010cited by this paper
• Mucoidy, Quorum Sensing, Mismatch Repair and Antibiotic Resistance in Pseudomonas aeruginosa from Cystic Fibrosis Chronic Airways Infections

  2010cited by this paper
• Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis

  2009cited by this paper
• Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media.

  2008cited by this paper
• Poor clinical outcomes associated with a multi‐drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population

  2008cited by this paper
• Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient.

  2008cited by this paper
• Pseudomonas aeruginosa diversity in distinct paediatric patient groups.

  2008cited by this paper
• In vitro Activities of Various Antibiotics, Alone and in Combination with Colistin Methanesulfonate, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients

  2008cited by this paper
• Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.

  2008cited by this paper
• Chryseobacterium respiratory tract infections in patients with cystic fibrosis.

  2007cited by this paper
• Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.

  2007cited by this paper
• Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.

  2007cited by this paper
• Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts?

  2007cited by this paper
• Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients

  2006cited by this paper
• Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.

  2006cited by this paper
• In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

  2005cited by this paper
• Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips

  2005cited by this paper
• Detection of Pseudomonas aeruginosa in patients with cystic fibrosis.

  2005cited by this paper
• Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections

  2005cited by this paper
• Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.

  2004cited by this paper
• Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

  2004cited by this paper
• Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.

  2004cited by this paper
• Multiresistant non-fermentative Gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study

  2004cited by this paper
• Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients

  2004cited by this paper
• Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units

  2004cited by this paper
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

  2003cited by this paper
• Whole-Genome Sequence Variation among Multiple Isolates of Pseudomonas aeruginosa

  2003cited by this paper

• Colistin Resistance: From Laboratory Research to Modern Clinical Management

  2026cites this paper
• Evaluation of the relationship between quorum sensing system genes and antibiotic resistance in isolated Pseudomonas aeruginosa from cystic fibrosis patients

  2025cites this paper
• Mesenchymal Stromal Cell Extracellular Vesicles Reduce Pseudomonas Biofilm Formation, and let-7b-5p Loading Confers Additional Anti-Inflammatory Effects.

  2025cites this paper
• Emergence of extensively and pan-drug resistance in clinical bacterial isolates: A systematic scoping review from Ethiopian public health perspective

  2025cites this paper
• Changes in Antibiotic Resistance of Children with Cystic Fibrosis and Impact on Clinical Outcomes

  2025cites this paper
• Zinc sulfate acts as an efflux pump inhibitor on Pseudomonas aeruginosa clinical isolates

  2025cites this paper
• Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reduce Pseudomonas-biofilm formation and inflammation in CF Bronchial Epithelial Cells

  2025cites this paper
• Patients’ perspectives on antimicrobial resistance in chronic respiratory disease: an AMR-Lung/European Lung Foundation global patient survey

  2025cites this paper
• Separability of antibacterial and membranolytic activity in the human host defense peptide LL-37

  2025cites this paper
• Global epidemiology of high priority and pandemic Pseudomonas aeruginosa in pets, livestock, wild and aquatic animals: A systematic review and meta-analysis.

  2025cites this paper
• Experiences and theory reveal antimicrobial blue light killing efficiency decrease as biofilm grows in a Pseudomonas aeruginosa model

  2025cites this paper
• Antimicrobial activity of new anti-Pseudomonas beta-lactam-beta-lactamase inhibitors against Pseudomonas aeruginosa respiratory isolates recovered during the study for Monitoring Antimicrobial Resistance Trends (SMART) program in France (2016-2022).

  2025cites this paper
• Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon

  2025cites this paper
• Overcoming Pseudomonas aeruginosa in Chronic Suppurative Lung Disease: Prevalence, Treatment Challenges, and the Promise of Bacteriophage Therapy

  2025cites this paper
• De novo cysteine biosynthesis in Pseudomonas aeruginosa: Characterization of the two main cysteine synthase isoforms

  2025cites this paper
• Prevalence of Antibiotic Resistance Determinants in Carbapenem-Resistant Pseudomonas aeruginosa: Focus on Class 1 and 2 Integrons and blaIMP Gene

  2025cites this paper
• Phenotypic and Molecular Analysis of Fosfomycin Resistance Among P. aeruginosa Isolates from Cystic Fibrosis Patients

  2025influential citation
• Characterizing Spatiotemporal Expansion of Pseudomonas aeruginosa Communities in Polymer and Mucin Gel Environments

  2025cites this paper
• Directed evolution of phages in biofilms enhances Pseudomonas aeruginosa control through improved lipopolysaccharide recognition

  2025cites this paper
• Antibiotic Resistance Patterns of Pseudomonas aeruginosa Bacterial Species Isolated from Various Clinical Samples

  2024cites this paper
• Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa.

  2024cites this paper
• Pseudomonas aeruginosa transcriptome analysis of metal restriction in ex vivo cystic fibrosis sputum

  2024cites this paper
• Tetramerization is essential for the enzymatic function of the Pseudomonas aeruginosa virulence factor UDP-glucose pyrophosphorylase

  2024cites this paper
• The Impact of Antimicrobial Resistance in Cystic Fibrosis

  2024cites this paper
• Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

  2024cites this paper
• Genomic Comparative of Pseudomonas aeruginosa Small Colony Variant, Mucoid and Non-mucoid Phenotypes Obtained from a Patient with Cystic Fibrosis During Respiratory Exacerbations

  2024cites this paper
• Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage

  2024cites this paper
• Spatiotemporal distribution of the planktonic microbiome and antibiotic resistance genes in a typical urban river contaminated by macrolide antibiotics.

  2024cites this paper
• Characterization of acquired β-lactamases in Pseudomonas aeruginosa and quantification of their contributions to resistance

  2024cites this paper
• Prevalence of colistin resistance in clinical isolates of Pseudomonas aeruginosa: a systematic review and meta-analysis

  2024cites this paper
• Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges

  2024cites this paper
• Multi-year comparison of VITEK MS performance for identification of rarely encountered pathogenic Gram-negative organisms (GNOs) in a large integrated Canadian healthcare region

  2024cites this paper
• Reduced prevalence of phage defense systems in Pseudomonas aeruginosa strains from cystic fibrosis patients

  2024cites this paper
• High-risk Pseudomonas aeruginosa clones harboring β-lactamases: 2024 update

  2024cites this paper
• Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future

  2023cites this paper
• AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease

  2023cites this paper
• The Impact of Pseudomonas aeruginosa Infection in Adult Cystic Fibrosis Patients—A Single Polish Centre Study

  2023cites this paper
• Extracellular vesicles secreted by primary human bronchial epithelial cells reduce Pseudomonas aeruginosa burden and inflammation in cystic fibrosis mouse lung

  2023cites this paper
• THỰC TRẠNG NHIỄM KHUẨN VÀ MỨC ĐỘ KHÁNG KHÁNG SINH TRÊN BỆNH NHÂN ĐIỀU TRỊ TẠI BỆNH VIỆN 199 - BỘ CÔNG AN

  2023cites this paper
• Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains

  2023cites this paper
• Analysis of Pseudomonas aeruginosa transcription in an ex vivo cystic fibrosis sputum model identifies metal restriction as a gene expression stimulus

  2023cites this paper
• Antimicrobial Resistance, Genetic Lineages, and Biofilm Formation in Pseudomonas aeruginosa Isolated from Human Infections: An Emerging One Health Concern

  2023cites this paper
• Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development

  2023cites this paper
• Advances in Nanotechnology for Biofilm Inhibition

  2023cites this paper
• Flowering phenophases influence the antibacterial and anti-biofilm effects of Thymus vulgaris L. essential oil

  2023cites this paper
• Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

  2023cites this paper
• Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by Pseudomonas aeruginosa: A Narrative Review of Current Evidence

  2022cites this paper
• An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli

  2022cites this paper